Meeting Banner
Abstract #0731

Development of advanced multiparametric MRI biomarkers of Alzheimer’s disease

Ashley M. Stokes1, Zhiqiang Li2, James G. Pipe2, Richard J. Caselli3, Marwan N. Sabbagh4, and Leslie C. Baxter5

1Translational Bioimaging Group, Barrow Neurological Institute, Phoenix, AZ, United States, 2Magnetic Resonance Technology Design Group, Barrow Neurological Institute, Phoenix, AZ, United States, 3Mayo Clinic - Arizona, Scottsdale, AZ, United States, 4Neurology, Alzheimer’s and Memory Disorders, Barrow Neurological Institute, Phoenix, AZ, United States, 5Human Brain Mapping Laboratory, Barrow Neurological Institute, Phoenix, AZ, United States

The goal of this project is to establish advanced MRI signatures of each stage of Alzheimer’s disease (AD), including preclinical, mild cognitive impairment (MCI), and dementia stages. These advanced imaging methods will allow us to non-invasively investigate the underlying neurobiological changes that precede cognitive impairment. While structural MRI is known to change with disease progression, advanced MR imaging may provide more specific signatures of disease progression. The asymptomatic and MCI phases represent a clear potential for early intervention, and the non-invasive methods developed here may identify patients along the clinical trajectory of AD.

This abstract and the presentation materials are available to members only; a login is required.

Join Here